ANI Pharmaceuticals President and CEO Lalwani Nikhil sold 5,400 shares at $71 each on September 15, 2026. After the transaction, he held 339,089 shares, while the sale equaled about 1.6% of his prior holding, giving investors the disclosed size of the transaction relative to his stake.
Key Highlights
- Lalwani Nikhil held 339,089 shares after the transaction.
- The sale represented about 1.6% of his prior shares holding.
- The filing reports SEC transaction code S for the trade.
ANI PHARMACEUTICALS INC (NASDAQ: ANIP) saw its PRESIDENT & CEO, Lalwani Nikhil, sell 5,400 shares at $71 per share. The transaction took place on September 15, 2026, with the reported price applying to each share transferred.
Post-Transaction Holding: 339,089 Shares
The transaction is reported under SEC transaction code S. Lalwani Nikhil held 339,089 shares after the transaction. The reported sale represented about 1.6% of his prior shares holding. ANI Pharmaceuticals Inc identified Lalwani Nikhil as its PRESIDENT & CEO in the transaction details. Transaction code S denotes an open-market or private sale.
FAQs
Q: Did ANI Pharmaceuticals CEO Lalwani Nikhil sell shares at $71?
A: Yes. The filing reports that Lalwani Nikhil, ANI Pharmaceuticals’ PRESIDENT & CEO, sold 5,400 shares at $71 per share on September 15, 2026.
Q: How many ANI Pharmaceuticals shares did Lalwani Nikhil own after the sale?
A: The filing states that Lalwani Nikhil owned 339,089 ANI Pharmaceuticals shares following the transaction. This is the reported post-transaction holding.
Q: What does transaction code S mean for the ANI Pharmaceuticals trade?
A: The filing lists SEC transaction code S for the trade. It also reports that the transaction represented about 1.6% of Lalwani Nikhil’s prior shares holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.